Company: MYSEW
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076607
Chunk: 103

Company: Myseum, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 103
---
 Increase (as defined in the Series
B COD) and shall not be entitled to vote on any other matter. The shares of Series B Preferred Stock shall be voted, without action by
the holder, on the Authorized Stock Increase in the same proportion as shares of Common Stock are voted (excluding any shares of Common
Stock that are not voted) on the Authorized Stock Increase. The Series B Preferred shall not have the right to vote and/or consent on
any matter other than an Authorized Stock Increase Proposal. The Series B Preferred Stock shall not be entitled to participate in any
distribution of assets or rights upon any liquidation, dissolution or winding up of the Company, shall not be convertible into Common
Stock or any other security of the Company, and shall not be entitled to any dividends or distributions.

16

MYSEUM, INC. AND SUBSIDIARIES

(FORMERLY DATCHAT, INC.)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2025 AND 2024

(Unaudited)

The outstanding shares of Series B preferred shall
be redeemed in whole, but not in part (i) if such redemption is ordered by the board of directors, or (ii) automatically and effective
immediately after the effectiveness of an anticipated Authorized Stock increase. The aggregate consideration payable for the outstanding
Series B Preferred redeemed in the redemption shall be $10 in cash (the “Redemption Price”).

From and after the time at which the shares of
Series B Preferred Stock is called for Redemption (whether automatically or otherwise) in accordance with Series B COD, such shares of
Series B Preferred Stock shall cease to be outstanding, and the only right of the former holder of such shares of Series B Preferred Stock,
as such, will be to receive the applicable Redemption Price. The shares of Series B Preferred Stock redeemed by the Company pursuant to
the Series B COD shall be automatically retired and restored to the status of an authorized but unissued share of Preferred Stock, effective
immediately after such Redemption.

On August 4, 2023, the Company issued 2,000,000
of Series B preferred for aggregate cash of $1,000.

Common Stock

Sale of Common Stock and Warrants

2024

On January 16, 2024, the Company entered into
an underwriting agreement (the “Underwriting Agreement”) with EF Hutton LLC (the “Representative”), as the representative
of the underwriters named therein (the “